The Biotech Stock Research, LLC team has 26 dev-stage biotech companies under formal coverage. We are independent, with no bankers, no trading desk, we don't run a fund, and we're not paid by the companies we cover. See why PMs of funds with billions in assets make our research a regular read.
In today's development-stage biotech marketplace, quality fundamental research is not enough. A tactical approach to investing in this tricky space is just as important. BSR+Alpha marries quant, fundamental, and options analyses to give investors an edge. BSR+Alpha is what's next in biotechnology sector research.
